WallStreetZenWallStreetZen

NASDAQ: BRNS
Barinthus Biotherapeutics PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their BRNS stock forecasts and price targets.

Forecast return on equity

Is BRNS forecast to generate an efficient return?

Company
-58.07%
Industry
50.34%
Market
-25.4%
BRNS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BRNS forecast to generate an efficient return on assets?

Company
-45.88%
Industry
15.86%
BRNS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BRNS earnings per share forecast

What is BRNS's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.86
Avg 2 year Forecast
-$1.43
Avg 3 year Forecast
-$1.46

BRNS revenue growth forecast

How is BRNS forecast to perform vs Biotechnology companies and vs the US market?

Company
-61.53%
Industry
253.76%
Market
13.11%
BRNS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BRNS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BRNS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BRNS$1.36N/AN/A
ACRV$1.74$8.00+359.77%Buy
SNTI$2.08$9.67+364.76%Strong Buy
TELO$1.64N/AN/A
SER$5.15$15.00+191.26%Buy
View Top Biotech Stocks

Barinthus Biotherapeutics Stock Forecast FAQ

What is BRNS's earnings growth forecast for 2025-2027?

(NASDAQ: BRNS) Barinthus Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.15%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.82%.

Barinthus Biotherapeutics's earnings in 2025 is -$69,426,000.On average, 1 Wall Street analyst forecast BRNS's earnings for 2025 to be -$75,735,906, with the lowest BRNS earnings forecast at -$75,735,906, and the highest BRNS earnings forecast at -$75,735,906. On average, 1 Wall Street analyst forecast BRNS's earnings for 2026 to be -$58,227,067, with the lowest BRNS earnings forecast at -$58,227,067, and the highest BRNS earnings forecast at -$58,227,067.

In 2027, BRNS is forecast to generate -$59,448,614 in earnings, with the lowest earnings forecast at -$59,448,614 and the highest earnings forecast at -$59,448,614.

If you're new to stock investing, here's how to buy Barinthus Biotherapeutics stock.

What is BRNS's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: BRNS) forecast ROE is -58.07%, which is considered weak.

What is BRNS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BRNS) Barinthus Biotherapeutics's current Earnings Per Share (EPS) is -$1.73. On average, analysts forecast that BRNS's EPS will be -$1.86 for 2025, with the lowest EPS forecast at -$1.86, and the highest EPS forecast at -$1.86. On average, analysts forecast that BRNS's EPS will be -$1.43 for 2026, with the lowest EPS forecast at -$1.43, and the highest EPS forecast at -$1.43. In 2027, BRNS's EPS is forecast to hit -$1.46 (min: -$1.46, max: -$1.46).

What is BRNS's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: BRNS) forecast ROA is -45.88%, which is lower than the forecast US Biotechnology industry average of 15.86%.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.